文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

自噬在脓毒症急性肾损伤发病机制与治疗中的作用进展

[The advances on autophagy the pathogenesis and treatment in septic acute kidney injury].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论综述指出自噬在脓毒症急性肾损伤中起关键保护作用,多种靶向自噬的信号通路与药物正被开发用于缓解该损伤。

本文为综述,总结自噬在脓毒症急性肾损伤(SAKI)发病机制与治疗中的最新进展。传统观点认为SAKI主要机制为肾血流减少、肾灌注不足、炎症反应及微循环障碍导致肾小管细胞缺血坏死;新近研究表明自噬等程序性细胞死亡过程日益重要。自噬通过调节炎症与免疫反应、清除受损细胞器、维持细胞内环境稳定发挥关键保护作用;mTOR、AMPK、NF-κB、Sirtuins、Beclin-1、TLR等信号通路与分子参与SAKI发生。当前治疗包括液体管理、感染控制、内环境平衡维持及肾脏替代治疗,但死亡率仍高;越来越多药物正通过调节自噬来缓解SAKI。

要点

  • 自噬是程序性细胞内降解过程,细胞经溶酶体降解胞质成分以维持代谢需要与细胞内稳态、更新细胞器。
  • SAKI时自噬通过调节炎症与免疫反应、清除受损细胞器、维持细胞内环境稳定发挥关键保护作用。
  • mTOR、AMPK、NF-κB信号通路及Sirtuins、Beclin-1、TLR等靶向自噬的信号通路与分子参与SAKI发生。
  • 当前SAKI治疗策略包括液体管理、感染控制、维持内环境平衡及肾脏替代治疗,但死亡率仍高。
  • 越来越多药物正通过调节自噬来缓解SAKI,本文旨在为开发SAKI新药提供思路。

适用人群与场景

  • 脓毒症患者,尤其是并发急性肾损伤(SAKI)者;SAKI是脓毒症最常见并发症之一,发生AKI提示病情危重、预后不良。

处置流程与药物剂量

  • 当前SAKI治疗策略包括液体管理、感染控制、维持内环境平衡及肾脏替代治疗;但死亡率仍高。

研究设计与关键结果

  • 综述汇总:传统观点认为SAKI主要机制为脓毒症所致肾血流减少、肾灌注不足、炎症反应及微循环障碍,继而导致肾小管细胞缺血坏死;新近研究表明自噬等程序性细胞死亡过程发挥日益重要的作用。
  • 综述汇总:SAKI时自噬通过调节炎症与免疫反应、清除受损细胞器、维持细胞内环境稳定等机制发挥关键保护作用。
  • 综述汇总:mTOR、AMPK、NF-κB信号通路及Sirtuins、Beclin-1、TLR等靶向自噬的信号通路与分子参与SAKI发生。
  • 综述汇总:越来越多药物正通过调节自噬来缓解SAKI。

对床旁实践的改变

  • 作者认为自噬在脓毒症介导的AKI中起关键保护作用,越来越多药物正通过调节自噬来缓解SAKI,本文旨在为开发SAKI新药提供思路。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「证据类型、等级与局限」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection. Septic acute kidney injury (SAKI) is one of the most common complications of sepsis, and the occurrence of acute kidney injury (AKI) indicates that the patient's condition is critical with a poor prognosis. The traditional view holds that the main mechanism of SAKI is the reduction of renal blood flow, inadequate renal perfusion, inflammatory response, and microcirculatory dysfunction caused by sepsis, which subsequently leads to ischemia and necrosis of renal tubular cells. Recent research findings indicate that processes such as autophagy and other forms of programmed cell death play an increasingly important role. Autophagy is a programmed intracellular degradation process and is a form of programmed cell death. Cells degrade their cytoplasmic components via lysosomes, breaking down and recycling intracellular constituents to meet their metabolic needs, maintain intracellular homeostasis, and renew organelles. During SAKI, autophagy plays a crucial protective role through various mechanisms, including regulating inflammation and immune responses, clearing damaged organelles, and maintaining stability in the intracellular environment. In recent years, the role of autophagy in the pathogenesis and treatment of SAKI has received widespread attention. Research has confirmed that various intracellular signaling pathways and signaling molecules targeting autophagy [such as mammalian target of rapamycin (mTOR) signaling pathway, AMP-activated protein kinase (AMPK) signaling pathway, nuclear factor-κB (NF-κB) signaling pathway, and Sirtuins (SIRT), autophagy associated factor Beclin-1, and Toll-like receptor (TLR)] are involved in the development of SAKI. Due to the complex pathogenesis of SAKI, current treatment strategies include fluid management, infection control, maintenance of internal environment balance, and renal replacement therapy; however, the mortality remains high. In recent years, it has been found that autophagy plays a critical protective role in sepsis-mediated AKI. As a result, an increasing number of drugs are being developed to alleviate SAKI by regulating autophagy. This article reviews the latest advances in the role of autophagy in the pathogenesis and treatment of SAKI, with the aim of providing insights for the development of new drugs for SAKI patients.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Tian Z, Zhang J, Nie S, et al. [The advances on autophagy the pathogenesis and treatment in septic acute kidney injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40017369. doi:10.3760/cma.j.cn121430-20240904-00748

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。